PV Bulletin

Cancellation of Registered Complementary & Alternative Product

The NPRA has cancelled the registration of several complementary and alternative products due to the detection of undeclared scheduled poisons.

Primary source: Cancellation of Notified Cosmetic Products

PV Impact Brief

Urgency: HighConfidence: high

What changed

Product registration has been cancelled for several products found to contain scheduled poisons, effective August 5, 2026.

Why it matters

The presence of undeclared scheduled poisons poses serious health risks to consumers. Rapid regulatory actions are crucial to ensure public safety and compliance with drug regulations.

Action needed

Sellers and distributors are mandated to cease the sale and distribution of the affected products immediately and comply with penalties for non-compliance, which may include fines up to RM50,000 or imprisonment.

Relevant for
Regulatory Intelligence Lead
Processes impacted
Signal Management
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Regulatory action details

Action type
safety_signal
Publication date
2026-08-16T06:37:17.000Z

PV internal implications

Sellers and distributors are mandated to cease the sale and distribution of the affected products immediately and comply with penalties for non-compliance, which may include fines up to RM50,000 or imprisonment.

View regulator source

Source document details

Exact policy details

Product Registration Cancellation Date
2026-08-05
Applies to: All registered complementary and alternative products listed in the document.
Products with undeclared chemicals or scheduled poisons will be removed from the market. · p. 1 · High · Source
Adverse Effects Warning
Serious adverse effects may occur.
Applies to: Consumers using the affected products.
The use of these adulterated products can lead to severe adverse effects. · p. 1 · High · Source
Legal Penalty for Sellers
Fine up to RM50,000 or imprisonment up to 5 years.
Applies to: Sellers and distributors of canceled products.
Individuals found violating this regulation can face significant penalties. · p. 2 · High · Source

Extracted documents

PDF embedded text was unavailable or too sparse; OCR fallback used. PDF OCR skipped because Ghostscript rendering is unavailable or failed.

Evidence and confidence

Confidence: highSource updated: Aug 16, 2026

Full briefing

Practical implication

Sellers and distributors are mandated to cease the sale and distribution of the affected products immediately and comply with penalties for non-compliance, which may include fines up to RM50,000 or imprisonment.

The National Pharmaceutical Regulatory Agency (NPRA) in Malaysia has announced the cancellation of the registration of specific complementary and alternative products following the discovery of undeclared scheduled poisons, including diphenhydramine and glibenclamide, in these products. Consumers are urged to stop using these products and consult healthcare professionals if they experience any adverse effects.

What changed: Product registration has been cancelled for several products found to contain scheduled poisons, effective August 5, 2026.

Why it matters: The presence of undeclared scheduled poisons poses serious health risks to consumers. Rapid regulatory actions are crucial to ensure public safety and compliance with drug regulations.

Practical implication: Sellers and distributors are mandated to cease the sale and distribution of the affected products immediately and comply with penalties for non-compliance, which may include fines up to RM50,000 or imprisonment.

View original source

  • Source: NPRA (Malaysia) - Press Releases
  • Published at source: 2026-08-16T06:37:17.000Z
  • Discovered by monitor: 2026-08-16T06:37:45.460Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Safety Signal#Safety Signals#Malaysia#Npra.gov.my#Source-ingestion#Regulator-monitor

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward